Peregrine Pharma (PPHM) Misses Q1 EPS by 1c
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Peregrine Pharma (NASDAQ: PPHM) reported Q1 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $5.61 million versus the consensus estimate of $13.09 million.
Peregrine Pharma sees Q2 2017 revenue of $20 million, versus the consensus of $12.5 million.
- Company Reaffirms Revenue Projection of $50 - $55 Million for Full FY 2017 with Growing Backlog of Business
For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Gold (ABX) Tops Q3 EPS by 4c
- Encore Wire (WIRE) Misses Q2 EPS by 27c
- DDR Corp. (DDR) Tops Q3 FFO by 2c
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!